Skip to main content
Clinical Trials/NCT06486805
NCT06486805
Completed
Phase 4

The Effect of N-Acetylcysteine on Liver Functions After Mitral Valve Replacement: A Randomized Controlled Trial

Kasr El Aini Hospital1 site in 1 country54 target enrollmentJune 30, 2024

Overview

Phase
Phase 4
Intervention
normal saline
Conditions
Oxidative Stress
Sponsor
Kasr El Aini Hospital
Enrollment
54
Locations
1
Primary Endpoint
Malondialdahyde (MDA)
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

This study aimed at the impact of the N-acetyl cysteine on the improvement of liver function subsequently on-pum mitral valve replacement. Following a clinical trial design, 54 candidates of on-pump MVR, aged 18 to 70 years, with normal liver and renal function were selected. The candidates were randomly divided into intervention: IV150 mg/ kg N-acetyl cysteine over 15 min, and control groups (normal saline as placebo) (n = 27 in each group).

Detailed Description

In a randomized controlled prospective study conducted in a teaching hospital, after approval by the ethics committee and informed consent, 54 candidates for on-pump MVR, aged 18 to 70 years, with normal liver and renal function, were selected. The candidates were randomly divided into intervention: IV 150 mg/ kg N-acetyl cysteine over 15 min then 50 mg/kg over 4 hrs for 3 days, and control groups (normal saline as placebo) (n = 27 in each group).and we will assess the effect of NAC on intra-operative hemodynamics and post-operative its protective rule against oxidative stress and liver dysfunction.

Registry
clinicaltrials.gov
Start Date
June 30, 2024
End Date
December 30, 2024
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Kasr El Aini Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Mohamed Mohamed Elhaddad

Assisstent professor

Kasr El Aini Hospital

Eligibility Criteria

Inclusion Criteria

  • Age from 18 to 70 years
  • Both sexes
  • Patients undergoing on-pump elective MVR with cold cardioplegia.

Exclusion Criteria

  • Patient refusal.
  • Allergy to any of the study medications.
  • Emergency procedures.
  • systolic dysfunction, left ventricular ejection fraction \<40%.
  • Pre-existing hepatic dysfunction, which is defined as an increase in liver enzymes AST and ALT \>10 times the baseline.
  • chronic use of drugs affecting liver functions, e.g., NSAIDs, steroids, and anticonvulsants.

Arms & Interventions

control

received the same volume of normal saline as placebo

Intervention: normal saline

NAC

received 150 mg/kg NAC in 200 ml of 5% glucose over 15 min through the central line after induction of anesthesia and intubation followed by 50 mg/kg of NAC in 500 ml of 5% glucose over 4 h

Intervention: N acetyl cysteine

Outcomes

Primary Outcomes

Malondialdahyde (MDA)

Time Frame: Postoperative day one

MDA is a marker of oxidative stress and one of the end-products of lipid peroxidation. MDA level reflects the degree of lipid peroxidation.

Secondary Outcomes

  • liver function tests(preoperative ,first ,and,second post operative days)
  • hemodunamics(intraoperative)
  • tissue perfusion(preoperative ,first ,and,second post operative days)
  • MDA(preoperative and second postoperative day)
  • extubation time(postoperative 24 hr.)

Study Sites (1)

Loading locations...

Similar Trials